Summary
A triple monoamine reuptake inhibitor developed by Hoffman-LaRoche in the 1970s as an antidepressant but discontinued, probably due to high abuse potential. Has not become popular as a recreational drug at this time. Acts as an SNDRI, mostly inhibits dopamine and noradrenaline.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 30-40mg | 40-60mg | - | 60-80mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Peak | Total |
|---|---|---|
| Oral | 4.0-6.0 hrs | 240-0 min |
Tolerance
Build-up
develops over days to weeks of regular use
Reset
3–7 days for acute tolerance; longer for full reset
Effects
Positive
- Stimulation
- Mental/physical stimulation
Negative
- Increased heart rate
- Insomnia
- Pupil dilation
- Nausea
- Vasoconstriction
- Restlessness
- Sedation
- Decreased appetite
Positive
- Alertness enhancement
- Euphoria
- Cognitive euphoria
- Wakefulness
- Empathy
Negative
- Anxiety
- Confusion
- Compulsive redosing
- Talkativeness
- Time distortion
Positive
- Increased music appreciation
- Color enhancement
- Tactile enhancement
- Brightened colour
Negative
- Light sensitivity
- Disinhibition
- Appetite suppression
- Dehydration
- Dulled perception
- Drifting